Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT06206902 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, open, Phase I clinical study to evaluate the safety and tolerability of F01 in subjects with relapsed/refractory non-Hodgkin lymphoma, and to determine MTD and/or RD.

NCT ID: NCT06203652 Recruiting - Lymphoma Clinical Trials

The Pathogenesis and Prognostic Factors of Lymphoma

Start date: June 5, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

NCT ID: NCT06190301 Recruiting - Clinical trials for Primary Ocular Adnexal MALT Lymphoma

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Start date: January 11, 2024
Phase: N/A
Study type: Interventional

This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.

NCT ID: NCT06189391 Recruiting - Clinical trials for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Start date: March 4, 2021
Phase: Phase 1
Study type: Interventional

This study aims to provide a basis for further clinical development of CN201.

NCT ID: NCT06180174 Recruiting - Clinical trials for Non Hodgkin Lymphoma

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma.

NCT ID: NCT06173518 Recruiting - Clinical trials for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Start date: November 16, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL)

NCT ID: NCT06160362 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

This is a study for patients who have been previously treated for NHL. The purpose of this study is to determine the safety and feasibility of double-target CART-19 and 20 cells to the patients with relapsed and refractory CD19+/CD20+ NHL.

NCT ID: NCT06156774 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Start date: April 18, 2024
Phase:
Study type: Observational

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

NCT ID: NCT06149169 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Start date: August 17, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.

NCT ID: NCT06139406 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Start date: December 6, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) [Part A: Dose Escalation] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs [Part B: Dose Expansion].